Tag: legal claims
-
Viagra MDL For Melanoma Side Effect Legal Claims May Expand To Include Cialis Lawsuits, Soon, And Levitra Cases, Later
There Is An Apparent Melanoma Skin Cancer Link For Each Of These ED Drugs Given How PDE5 Inhibition Augments Tumor Cell Invasiveness (Posted by Tom Lamb at DrugInjuryWatch.com) _________________________________________________________________________________ UPDATE: IN RE: Viagra…
-
YAZ / Yasmin Products Liability Litigation: February 2014 Bayer Information About The Number Of Claims, Lawsuits, And Settlements
While 2013 Annual Report Includes Gianvi And Ocella Drug Injury Cases, The Only Mention Of Beyaz And Safyral Legal Cases Is Regarding Patent Disputes (Posted by Tom Lamb at DrugInjuryWatch.com)The YAZ / Yasmin litigation…
-
September 2013 NuvaRing Update By Merck Reveals More Than 1,700 Lawsuits Filed Since This Products Liability Litigation Started In 2007
Serious Injury And Death Cases Involve Blood Clots Leading To DVT And/Or PE Events As Well As Heart Attacks And Strokes In Women Of Various Ages (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE:"Merck to…
-
YAZ / Yasmin / Ocella / Gianvi Blood Clot Lawsuits That Are Not Settled Yet: Number Increases, Indicating That These Legal Claims Continue To Be Filed In 2013
Bayer Has Paid $1.4 Billion In Settlements for Cases Involving Deep Vein Thrombosis (DVT) And/Or Pulmonary Embolism (PE), Also Called "Venous Clot Injuries" (Posted by Tom Lamb at DrugInjuryWatch.com)Previously, we reported that more than…
-
November 2012 Litigation And Settlements Update: YAZ, Yasmin, Ocella, And Gianvi Lawsuits
Bayer Has Settled Less Than Half The DVT And PE Blood Clot Claims Filed Or Cases Subject To Tolling Agreements (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2012 we received the Bayer Stockholders’ Newsletter…
-
Disturbing Information About NuvaRing Safety Found In Motions On Experts Recently Unsealed By Federal Court MDL Judge
Newly Available Expert Analysis Of Confidential Drug Company Data Reveals That NuvaRing Estrogen Levels In Studies Were A Cause For Concern, And The Method Of Reporting Was Misleading (Posted by Tom Lamb at DrugInjuryWatch.com)…